Prescribing Varenicline

Why Varenicline Still Matters

Tobacco kills more of your patients than every other substance combined, and it kills psychiatric patients disproportionately. People with mental illness and substance use disorders smoke at roughly twice the rate of the general population and account for nearly half of all cigarettes consumed in the country. They die years earlier, often of the cardiovascular and pulmonary disease that smoking drives, not of their psychiatric illness. And yet tobacco is the addiction we are most likely to leave off the problem list, shrug at, and never treat.

Varenicline is the most effective single pharmacotherapy we have for it. In a meta-analysis of over 100 trials, it was roughly twice as effective as either nicotine replacement therapy (NRT) or bupropion. In the head-to-head industry trials that supported its approval, continuous abstinence at one year ran about 22.5% on varenicline versus 15.5% on bupropion and 9% on placebo. No other single agent for smoking cessation beats it.

For years, two shadows hung over the drug and suppressed its use: a 2009 FDA black box warning for neuropsychiatric events (depression, agitation, suicidality) and a cardiovascular safety signal. Both have since been substantially walked back. The landmark EAGLES trial, a large, randomized, placebo-controlled study specifically designed to test the neuropsychiatric question and enrolling roughly 8,000 smokers, half of them with a psychiatric history, found no significant increase in moderate-to-severe neuropsychiatric events attributable to varenicline. On that evidence, the FDA removed the black box warning in 2016. A large cardiovascular safety trial likewise found no statistical increase in heart attack or stroke.

The upshot for practice: the drug that scared clinicians for a decade turns out to be well tolerated, including in exactly the psychiatric patients who need it most, and the safety concerns were overstated. This guide is about prescribing it confidently and correctly.

Part 1: Indications: Who Is Varenicline For?

FDA-Approved Use

• Smoking cessation / treatment of nicotine (tobacco) dependence. Approved by the FDA in 2006. That is the label indication, full stop.

The Evidence-Based Clinical Uses

The motivated adult smoker: the home turf. Any patient who smokes and is willing to make a quit attempt is a candidate. Varenicline is the most effective monotherapy, so for most patients ready to quit it is the reasonable first choice unless something specific pushes you toward NRT or bupropion (patient preference, prior good response, cost, or a wish to avoid a prescription).

Smokers with psychiatric illness. This is the population where varenicline is both most needed and, historically, most avoided. The EAGLES data are reassuring precisely here: smokers with bipolar disorder, depression, schizophrenia, and anxiety disorders tolerated varenicline no worse than psychiatric-free smokers, achieved comparable quit rates, and did not show an excess of serious neuropsychiatric events. In a smaller open-label psychiatric cohort, the most prominent side effects were the same ones everyone gets: nausea (about 38%), insomnia (about 30%), vivid dreams (about 13%), with no suicidality reported. The Carlat verdict is blunt and worth remembering: people with psychiatric illness tolerate varenicline just as well as those without.

Smokers who also drink: a two-for-one. Varenicline acts on nicotinic acetylcholine receptors that also modulate the reward from alcohol, and controlled data show it reduces alcohol consumption in smokers who drink. In a patient with comorbid tobacco and alcohol use, varenicline can address both (see the counterbalancing caution on reduced alcohol tolerance in Part 5).

Who Is Varenicline For, and Who Might Do Just as Well on NRT?

Reach for varenicline first when you want the highest-probability single-agent quit attempt: heavy dependence, prior failed attempts on NRT alone, or a patient who wants the strongest thing available. But be honest that the edge over combination NRT is real but not enormous. In an open-label, preference-based comparison, varenicline was only slightly more effective than NRT and no more effective than combination NRT (patch plus a short-acting form). The practical read: an NRT-amenable, motivated patient can do very well on well-optimized NRT, and cost or needle/pill aversion may legitimately steer the choice.

Part 2: Before You Start: Workup and Candidacy

Varenicline is refreshingly low-maintenance to start. There is no required baseline lab panel, no ECG, and no drug-level monitoring. The workup is clinical, not laboratory.

What to assess before writing the prescription

Who is a poorer candidate?

There are no absolute contraindications to varenicline beyond hypersensitivity. Use added caution and closer monitoring in:

• Patients with a history of serious depression, suicidal ideation, or psychosis (monitor, counsel, document; do not reflexively exclude)
• Heavy or ongoing alcohol use (reduced-tolerance caution)
• Severe renal impairment (dose adjustment)
• Pregnancy (limited data; see Special Populations)

Part 3: How to Start and Dose

The standard titration: memorize this

The entire schedule is built to reach the target dose gradually so that nausea, the dose-limiting side effect, stays tolerable.

1. Days 1–3
   0.5 mg once daily.
2. Days 4–7
   0.5 mg twice daily.
3. Day 8 onward
   1 mg twice daily (target/maintenance dose).

• Set the quit date for about day 8 (roughly one week after starting), so the patient is at, or reaching, the full 1 mg BID dose and has neuroadapted before they stop smoking. The point of starting a week early is that the patient keeps smoking during the run-in while the drug takes hold; the cigarettes gradually stop being rewarding.
• Standard course: 12 weeks. The pivotal trials treated for 12 weeks.
• Consider a second 12-week course (extending to 24 weeks total) in patients who have quit and want to consolidate; continued treatment reduces relapse compared with stopping at 12 weeks. Keep patients on it as long as they feel it is helping.

Take it with food and water

Nausea is the near-universal complaint, and the two simplest levers are the slow titration above and taking each dose with food and a full glass of water. Build this into the very first instruction you give.

Above-label dosing for non-responders

If a patient tolerates 1 mg BID but is still smoking at around week 6, options supported by more recent data include:

• Increasing to 3 mg/day (above the licensed 2 mg/day). In a phase-2 analysis of varenicline non-quitters, bumping to 3 mg/day raised the quit rate to about 20%, versus roughly 3% for those who simply continued at 2 mg/day. This is off-label but reasonable in a tolerating patient who hasn't quit.
• Adding a nicotine patch (combination therapy; see Part 7). The patch can be started before or alongside varenicline; the combination is well tolerated and more effective than either alone.

Behavioral support is not optional garnish

Every cessation attempt does better with counseling. You don't have to provide it all yourself: refer to the free, state-funded QuitLine (1-800-QUIT-NOW). Simple behavioral engineering multiplies the drug's effect: move cigarettes out of reach, get rid of the ashtray, relocate the chair the patient always smoked in, and plan a distracting activity for the times cravings peak. The medication blunts the pharmacology; the behavior change dismantles the cues.

Part 4: Monitoring: The Schedule

There is no laboratory monitoring for varenicline: no levels, no LFTs, no renal panel required for otherwise healthy patients, no ECG. Monitoring is entirely clinical, and it front-loads to the first month.

Nicotine withdrawal symptoms (agitation, irritability, cravings) are typically worst in the first few days and largely settle within the first week to first month. Insomnia usually resolves after the first month. Tell patients this up front so they don't mistake expected, self-limited discomfort for a reason to stop.

Part 5: Side Effects and How to Manage Them

The governing principle: varenicline's side effects are common but mostly mild, mostly early, and mostly manageable with dose timing, food, and patience. Nausea and sleep disturbance drive most discontinuations, and both are addressable.

Nausea: the headline side effect

The most frequent complaint by far. With the slow titration, incidence runs around 15%; with rapid dosing it climbs toward 40%. It is usually mild-to-moderate and tends to fade over the first weeks.

• Slow titration (the schedule in Part 3) is the primary prevention.
• Take every dose with food and a full glass of water.
• Reassure that it typically improves; most patients push through.
• If persistent and intolerable, a brief dose reduction (back to 0.5 mg BID) can be tried before re-escalating.

Insomnia

Reported by roughly 1 in 3 patients (about 30%). It usually resolves after the first month.

• Reassure and support; emphasize sleep hygiene.
• Confirm the dose isn't being taken too close to bedtime; the second daily dose can be moved earlier in the evening.
• A short course of an as-needed hypnotic is reasonable if sleep loss is significant.

Vivid dreams / nightmares

A characteristic and sometimes striking effect: vivid or abnormal dreams occur in around 13% of psychiatric patients and are commonly reported generally.

• Warn patients in advance so it isn't alarming.
• Clonidine 0.1–0.2 mg can reduce the dreams, and as a bonus it also blunts nicotine cravings and withdrawal, a genuine dual benefit.
• Moving the evening dose earlier may help.
• An as-needed benzodiazepine or hypnotic is an option if sleep is badly disrupted.

Other, generally milder effects

Headache, dizziness, and constipation are usually manageable with standard supportive measures and rarely force discontinuation.

The neuropsychiatric question: how to counsel accurately today

This deserves careful, calibrated treatment because it is where clinicians most often get it wrong in both directions.

The history: in 2009, on the basis of post-marketing reports, the FDA placed a black box warning on varenicline for neuropsychiatric events: depressed mood, agitation, hostility, suicidal ideation and behavior, and, rarely, psychosis. This warning drove a decade of underuse.

What the evidence then showed:

• A meta-analysis of over 10,000 smokers found no clear relationship between varenicline and depression, agitation, or suicidal ideation.
• The EAGLES trial (about 8,000 patients, half with psychiatric history) found no significant increase in moderate-to-severe neuropsychiatric events versus placebo, NRT, or bupropion, including in the psychiatric cohort.
• On this evidence, the FDA removed the black box warning in 2016.

How to counsel today: tell patients the truth, which is reassuring: large, rigorous studies did not confirm the feared neuropsychiatric risks, and the FDA removed the strong warning in 2016. At the same time, as with essentially every psychotropic, rare individual reactions can't be entirely excluded, so ask the patient, and where appropriate a family member, to watch for any real change in mood, agitation, or behavior and to stop the drug and call if it happens. That is honest, it doesn't inflate a risk the data don't support, and it doesn't pretend the historical warning never existed.

The cardiovascular question

A cardiovascular signal also circulated historically. A large randomized safety trial found no statistically significant increase in heart attack or stroke on varenicline, and the FDA's concern was correspondingly downgraded. Reassure accordingly: smoking itself is the overwhelming cardiovascular danger, and quitting is cardioprotective.

Alcohol tolerance: a genuine, if less-publicized, caution

In 2015 the FDA warned that varenicline may reduce alcohol tolerance, with reports of increased intoxication, unusual or aggressive behavior, blackouts, and, rarely, seizures. The mechanism is uncertain and the supporting evidence is limited, but it's worth a specific word to patients who drink: go easy on alcohol, especially early in treatment, and stop the drug and call if you have an unusual reaction to your usual amount.

Part 6: Drug Interactions

Varenicline is one of the cleanest psychotropics for interactions you will prescribe. Because it is minimally metabolized and cleared almost entirely by the kidneys, it has no clinically significant CYP450 interactions. You are not juggling enzyme induction or inhibition.

Nicotine (combination therapy)

• Mechanism: additive nicotinic receptor agonism.
• Significance: low-to-moderate, and clinically useful. Varenicline plus a nicotine patch is safe and more effective than either alone. In efficacy trials the patch was started about a week before varenicline; the combination did not add meaningfully to side effects.
• Management: watch for signs of excess nicotine (dizziness, nausea, tachycardia) and adjust; otherwise this is a legitimate tool for the tough-to-quit patient.

Alcohol

• Varenicline reduces alcohol consumption in smokers who drink, a beneficial effect via nicotinic modulation of alcohol reward.
• But the 2015 reduced-tolerance warning applies: counsel patients to moderate alcohol and report unusual intoxication or behavior.

What varenicline does NOT meaningfully interact with

The CYP450-metabolized drugs that complicate so much of psychopharmacology. Its renal-clearance, minimal-metabolism profile keeps it out of most interaction trouble.

Part 7: Combination and Above-Label Strategies

Varenicline is effective as monotherapy, but two moves extend it for stubborn cases:

Part 8: Special Populations

Pregnancy

Data are limited, and varenicline is generally avoided in pregnancy. For a pregnant smoker, the preferred approach is behavioral counseling first, with NRT considered if pharmacotherapy is needed. Smoking cessation itself is a high priority in pregnancy, but varenicline is not the first tool to reach for given the sparse safety data.

Lactation

Varenicline is excreted in breast milk; avoid if possible during breastfeeding. If a nursing mother and clinician judge the benefit to justify use, do so cautiously and in coordination with pediatrics.

Renal impairment

Varenicline is cleared almost entirely by the kidneys (about 90% or more excreted unchanged), so renal function drives dosing more than for most psychotropics.

• Mild-to-moderate impairment: standard dosing is generally fine.
• Severe renal impairment: a dose reduction is appropriate (a lower maximum, typically not exceeding once-daily dosing of the higher increment), with slower titration and closer clinical monitoring. Reduce and go slowly rather than pushing the standard 1 mg BID.

Psychiatric history: the EAGLES point, restated

• Varenicline is safe and effective in smokers with psychiatric illness: bipolar disorder, depression, schizophrenia, anxiety. EAGLES demonstrated comparable quit rates and no significant excess of serious neuropsychiatric events in this population.
• The practical implication: do not withhold varenicline from psychiatric patients. Monitor the first month, counsel on what to watch for, document your reasoning, and treat.

Elderly

Not specifically detailed in the pivotal literature. Given renal clearance and the age-related decline in renal function, check renal function and consider slower titration and a lower ceiling in older adults, and monitor tolerability closely.

Pediatric / adolescents

Not FDA-approved under 18, with limited safety data. Not a standard choice in this age group.

Part 9: Discontinuation

Varenicline is easy to stop from a pharmacologic standpoint. No taper is pharmacologically required: there is no withdrawal syndrome from the drug itself.

• Some clinicians taper gradually (stepping the dose down over a short period) to smooth any rebound in cravings or symptoms, but this is optional, not mandatory.
• The real discontinuation challenge is relapse to smoking. The clinical goal is to stay on treatment long enough to consolidate abstinence: at least 12 weeks after the quit date, extending to 24 weeks when helpful. Stopping too early raises relapse risk.
• Maintain behavioral support through and beyond discontinuation, since nicotine cravings can return after the drug is stopped.

Part 10: Varenicline vs the Alternatives

Head-to-head, varenicline is the most effective single agent for smoking cessation.

vs NRT (nicotine replacement therapy)

Varenicline is roughly twice as effective as NRT monotherapy in meta-analysis. NRT (about 16% quit at one year versus about 10% placebo) is the affordable, over-the-counter, well-tolerated standard, and combination NRT (patch plus a short-acting form) narrows the gap considerably: in preference-based comparison, varenicline was no more effective than combination NRT. NRT remains a legitimate first choice for the right patient, and it combines with varenicline for tough cases.

vs Bupropion (Zyban)

Varenicline wins on efficacy. In the pivotal trials, weeks 9 through 12 abstinence ran about 44% (varenicline) versus 30% (bupropion) versus 18% (placebo), and one-year continuous abstinence about 22.5% versus 15.5% versus 9%. Bupropion (an NDRI) is a reasonable alternative, especially in a patient with comorbid depression who might benefit from the antidepressant effect, but it carries its own seizure caution and is simply less effective for cessation.

The EAGLES trial: the reference point for safety

In about 8,000 smokers with and without psychiatric illness, varenicline outperformed both bupropion and NRT on efficacy without a significant excess of neuropsychiatric events. That is the trial that both established varenicline's efficacy edge in psychiatric populations and dismantled the black box warning.

So why was it underused?

The 2009 black box warning and the cardiovascular signal, both since walked back; cost (now easing as generic varenicline has become available); and a general reluctance to treat tobacco aggressively at all. A 2021 voluntary recall of brand-name Chantix over a nitrosamine impurity briefly disrupted supply, but generic varenicline is on the market. None of these are current clinical reasons to avoid the drug.

What varenicline uniquely or best delivers: the highest single-agent quit rate, demonstrated efficacy and safety in psychiatric smokers, a clean drug-interaction profile, and a bonus reduction in alcohol use for smokers who drink.

Mechanism: The Short Version

Varenicline is a selective partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, the main receptor through which nicotine drives its rewarding and dependence-producing effects, with high affinity for that site and antagonist activity at other nicotinic subtypes. Its dual action is the elegant part:

1. As a partial agonist, it modestly activates the alpha4beta2 receptor, producing enough downstream dopamine release in the mesolimbic reward pathway (nucleus accumbens) to relieve craving and blunt withdrawal, but less dopamine release than nicotine itself, so it doesn't reproduce the full reward of smoking.
2. As an occupant of the receptor, it blocks nicotine from binding, so that if the patient does smoke, the cigarette is far less rewarding. The reinforcement loop is broken from both ends.

Pharmacokinetically it is clean: half-life about 24 hours, oral bioavailability about 60%, minimal metabolism, and about 90% or more renal excretion unchanged, which is exactly why it has no meaningful CYP450 interactions and why renal function, not hepatic function, governs dosing.

Bedside Cheat Sheet